Francesco R Simonetti1, Mary F Kearney. 1. aHIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, USA bDepartment of Biomedical and Clinical Sciences, L. Sacco, Milan, Italy.
Abstract
PURPOSE OF REVIEW: HIV genetic diversity poses major challenges for the prevention, control, and cure of infection. Characterizing the diversity and evolution of HIV populations within the host provides insights into the mechanisms of HIV persistence during antiretroviral therapy (ART). This review describes the HIV diversity within patients, how it is affected by suppressive ART, and makes a case for early treatment after HIV infection. RECENT FINDINGS: HIV evolution is effectively halted by ART. However, cells that were infected prior to initiating therapy can proliferate to very high numbers both before and during treatment. Such clonal expansions result in the persistence of integrated proviruses despite therapy. These expanding proviruses have been shown to be a source for residual viremia during ART, and they may be a source for viral rebound after interrupting ART. SUMMARY: Plasma HIV RNA shows no evidence for evolution during ART, suggesting that HIV persistence is not driven by low-level, ongoing replication. The emergence of identical viral sequences observed in both HIV RNA and DNA is likely due to proliferation of infected cells. Early treatment restricts the viral population and reduces the number of variants that must be targeted for future therapeutic strategies.
PURPOSE OF REVIEW: HIV genetic diversity poses major challenges for the prevention, control, and cure of infection. Characterizing the diversity and evolution of HIV populations within the host provides insights into the mechanisms of HIV persistence during antiretroviral therapy (ART). This review describes the HIV diversity within patients, how it is affected by suppressive ART, and makes a case for early treatment after HIV infection. RECENT FINDINGS: HIV evolution is effectively halted by ART. However, cells that were infected prior to initiating therapy can proliferate to very high numbers both before and during treatment. Such clonal expansions result in the persistence of integrated proviruses despite therapy. These expanding proviruses have been shown to be a source for residual viremia during ART, and they may be a source for viral rebound after interrupting ART. SUMMARY: Plasma HIV RNA shows no evidence for evolution during ART, suggesting that HIV persistence is not driven by low-level, ongoing replication. The emergence of identical viral sequences observed in both HIV RNA and DNA is likely due to proliferation of infected cells. Early treatment restricts the viral population and reduces the number of variants that must be targeted for future therapeutic strategies.
Authors: Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin Journal: J Virol Date: 2010-10-06 Impact factor: 5.103
Authors: Hiromi Imamichi; Gerald Degray; Robin L Dewar; Peter Mannon; Michael Yao; Cheryl Chairez; Irini Sereti; Joseph A Kovacs Journal: J Infect Dis Date: 2011-07-15 Impact factor: 5.226
Authors: Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong Journal: J Infect Dis Date: 2010-10-12 Impact factor: 5.226
Authors: D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli Journal: Clin Infect Dis Date: 2010-03-15 Impact factor: 9.079
Authors: Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli Journal: Proc Natl Acad Sci U S A Date: 2009-05-22 Impact factor: 11.205
Authors: Marta E Bull; Gerald H Learn; Scott McElhone; Jane Hitti; David Lockhart; Sarah Holte; Joan Dragavon; Robert W Coombs; James I Mullins; Lisa M Frenkel Journal: J Virol Date: 2009-04-01 Impact factor: 5.103
Authors: Cristina Cellerai; Alexandre Harari; Hans Stauss; Sabine Yerly; Anna-Maria Geretti; Anne Carroll; Thynn Yee; Jonathan Ainsworth; Ian Williams; John Sweeney; Andrew Freedman; Margaret Johnson; Giuseppe Pantaleo; Sabine Kinloch-de Loes Journal: PLoS One Date: 2011-04-05 Impact factor: 3.240
Authors: Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron Journal: PLoS Med Date: 2010-08-10 Impact factor: 11.069
Authors: Marta Bull; Gerald Learn; Indira Genowati; Jennifer McKernan; Jane Hitti; David Lockhart; Kenneth Tapia; Sarah Holte; Joan Dragavon; Robert Coombs; James Mullins; Lisa Frenkel Journal: PLoS One Date: 2009-09-22 Impact factor: 3.240
Authors: Ifeanyi Ezeonwumelu; Inês Bártolo; Francisco Martin; Ana Abecasis; Teresa Campos; Ethan O Romero-Severson; Thomas Leitner; Nuno Taveira Journal: AIDS Res Hum Retroviruses Date: 2018-09-20 Impact factor: 2.205
Authors: Szu-Han Huang; Chase D McCann; Talia M Mota; Chao Wang; Steven M Lipkin; R Brad Jones Journal: Front Immunol Date: 2019-08-06 Impact factor: 7.561